Second primary neoplasms in patients with retinoblastoma
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
In a series of 882 retinoblastoma patients, 384 known to have the genetic form of the disease and 498 others, 30 patients developed second primary neoplasms. The spectrum of these second neoplasms is discussed in relation to the forms of treatment used for the retinoblastoma. Cumulative incidence rates of second tumours in the whole series are 2.0% at 12 years after diagnosis and 4.2% after 18 years. For patients with the genetic form of retinoblastoma the cumulative incidence rate after 18 years is 8.4% for all second neoplasms and 6.0% for osteosarcomas alone. The inherent risk among survivors from genetic retinoblastoma of developing an osteosarcoma, excluding all possible effects of treatment, is estimated to be 2.2% after 18 years. Within the field of radiation treatment the cumulative incidence rate for all second neoplasms after 18 years is 6.6% and for osteosarcomas alone 3.7%. There is some evidence that patients with genetic retinoblastoma are particularly sensitive to the carcinogenic effects of radiation. The results also suggest that the use of cyclophosphamide may increase the risk of second primary neoplasms in patients with genetic retinoblastoma. The incidence rates of second primary neoplasms in retinoblastoma survivors reported here are lower than those quoted for previously published series. Evidence from this and other papers strongly suggests an association between retinoblastoma and malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans
Carter, R. L. (1980) · Journal of Clinical Pathology · doi:10.1136/jcp.33.1.98-b · Cited by 3,456
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Retinoblastoma: Clues to Human Oncogenesis
Murphree, A. L., & Benedict, W. F. (1984) · Science · doi:10.1126/science.6320372 · Cited by 496
Second malignant neoplasms in children: an update from the Late Effects Study Group.
Meadows, A. T., Baum, E., Fossati-Bellani, F., Green, D., Jenkin, R. D., Marsden, B., Nesbit, M., Newton, W., Oberlin, O., & Sallan, S. G. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.4.532 · Cited by 481
Vogel, F. (1979) · Human Genetics · doi:10.1007/bf00284597 · Cited by 438
Second Nonocular Tumors in Retinoblastoma Survivors
Abramson, D. H., Ellsworth, R. M., Kitchin, F. D., & Tung, G. (1984) · Ophthalmology · doi:10.1016/s0161-6420(84)34127-6 · Cited by 436
RADIATION INDUCED NEOPLASIA FOLLOWING EXTERNAL BEAM THERAPY FOR CHILDREN WITH RETINOBLASTOMA
SAGERMAN, R. H., CASSADY, J. R., TRETTER, P., & ELLSWORTH, R. M. (1969) · American Journal of Roentgenology · doi:10.2214/ajr.105.3.529 · Cited by 222
Chromosome deletion in a case of retinoblastoma
LELE, K. P., PENROSE, L. S., & STALLARD, H. B. (1963) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1963.tb00209.x · Cited by 215
Retinoblastoma: a prototypic hereditary neoplasm.
Knudson, A. G. (1978) · PubMed · Cited by 199
Bilateral retinoblastoma with ectopic intracranial retinoblastoma: Trilateral retinoblastoma
Bader, J. L., Meadows, A. T., Zimmerman, L. E., Rorke, L. B., Voute, P. A., Champion, L. A. A., & Miller, R. W. (1982) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(82)90026-7 · Cited by 170
Cited by
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
“We manually curated the genetic alterations by BRAF, RAS (N/H/K), NF1, and TripleWT subtypes (Figure 4A) and found that RAS (N/H/K)-MAPKAKT, RB1/CDKN2A cell-cycle pathways, and MDM2/TP53 apoptosis pathways were altered in 91%, 69%, and 19% of cases, respectively.”
BackgroundInfluentialp53 functions as a cell cycle control protein in osteosarcomas.
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., & Vogelstein, B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 772
Bone Sarcomas Linked to Radiotherapy and Chemotherapy in Children
Tucker, M. A., D'Angio, G. J., Boice, J. D., Strong, L. C., Li, F. P., Stovall, M., Stone, B. J., Green, D. M., Lombardi, F., Newton, W., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171002 · Cited by 765
Toro, J. R., Travis, L. B., Wu, H. J., Zhu, K., Fletcher, C. D. M., & Devesa, S. S. (2006) · International Journal of Cancer · doi:10.1002/ijc.22239 · Cited by 680
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Marina, N., Gebhardt, M., Teot, L., & Gorlick, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-422 · Cited by 671
Cancer Incidence After Retinoblastoma: Radiation Dose and Sarcoma Risk
Wong, F. L. (1997) · JAMA · doi:10.1001/jama.1997.03550150066037 · Cited by 486
Dimaras, H., Corson, T. W., Cobrinik, D., White, A., Zhao, J., Munier, F. L., Abramson, D. H., Shields, C. L., Chantada, G. L., Njuguna, F., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.21 · Cited by 553
Horowitz, J. M., Park, S. H., Bogenmann, E., Cheng, J. C., Yandell, D. W., Kaye, F. J., Minna, J. D., Dryja, T. P., & Weinberg, R. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2775 · Cited by 530
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
“RB1 Hereditary retinoblastoma has been linked to inactivated copies of RB1 in the germline; however, such carriers have a fourfold to 80-fold elevated risk to develop melanoma (Draper et al. 1986; Sanders et al. 1989; Eng et al. 1993; Fletcher et al. 2004).”
Hereditary cancer: Two hits revisited
Knudson, A. G. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01366952 · Cited by 491
Kleinerman, R. A., Tucker, M. A., Tarone, R. E., Abramson, D. H., Seddon, J. M., Stovall, M., Li, F. P., & Fraumeni, J. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.054 · Cited by 487
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Friend, S. H., Horowitz, J. M., Gerber, M. R., Wang, X. F., Bogenmann, E., Li, F. P., & Weinberg, R. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9059 · Cited by 415
Structural Rearrangement of the Retinoblastoma Gene in Human Breast Carcinoma
T'Ang, A., Varley, J. M., Chakraborty, S., Murphree, A. L., & Fung, Y.-K. T. (1988) · Science · doi:10.1126/science.3175651 · Cited by 403
Malkin, D., Jolly, K. W., Barbier, N., Look, A. T., Friend, S. H., Gebhardt, M. C., Andersen, T. I., Børresen, A.-L., Li, F. P., Garber, J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262002 · Cited by 379
Chemoreduction in the Initial Management of Intraocular Retinoblastoma
Shields, C. L. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140530002 · Cited by 360
Cutaneous soft tissue sarcoma incidence patterns in the U.S.: An analysis of 12,114 cases
Rouhani, P., Fletcher, C. D. M., Devesa, S. S., & Toro, J. R. (2008) · Cancer · doi:10.1002/cncr.23571 · Cited by 342
Incidence of second primary tumours among childhood cancer survivors
Hawkins, M., Draper, G., & Kingston, J. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.200 · Cited by 332
Self-citationp107 is a suppressor of retinoblastoma development in pRb-deficient mice
Robanus-Maandag, E., Dekker, M., van der Valk, M., Carrozza, M.-L., Jeanny, J.-C., Dannenberg, J.-H., Berns, A., & te Riele, H. (1998) · Genes & Development · doi:10.1101/gad.12.11.1599 · Cited by 320
Lifetime Risks of Common Cancers Among Retinoblastoma Survivors
Fletcher, O., Easton, D., Anderson, K., Gilham, C., Jay, M., & Peto, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh058 · Cited by 312
Long-term risk of sarcoma following radiation treatment for breast cancer
Taghian, A., de Vathaire, F., Terrier, P., Le, M., Auquier, A., Mouriesse, H., Grimaud, E., Sarrazin, D., & Tubiana, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90783-z · Cited by 309
Evans, D. G. R., Birch, J. M., Ramsden, R. T., Sharif, S., & Baser, M. E. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.036319 · Cited by 301
Risk of Second Malignancies in Survivors of Retinoblastoma: More Than 40 Years of Follow-up
Marees, T., Moll, A. C., Imhof, S. M., de Boer, M. R., Ringens, P. J., & van Leeuwen, F. E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn394 · Cited by 286
Walter, A. W., Hancock, M. L., Pui, C. H., Hudson, M. M., Ochs, J. S., Rivera, G. K., Pratt, C. B., Boyett, J. M., & Kun, L. E. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3761 · Cited by 275
CDKN2A Mutations in Multiple Primary Melanomas
Monzon, J., Liu, L., Brill, H., Goldstein, A. M., Tucker, M. A., From, L., McLaughlin, J., Hogg, D., & Lassam, N. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381305 · Cited by 264
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Travis, L. B., Wahnefried, W. D., Allan, J. M., Wood, M. E., & Ng, A. K. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.41 · Cited by 264
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00105-5 · Cited by 262
Incidence and survival of malignant bone sarcomas in England 1979–2007
Whelan, J., McTiernan, A., Cooper, N., Wong, Y. K., Francis, M., Vernon, S., & Strauss, S. J. (2012) · International Journal of Cancer · doi:10.1002/ijc.26426 · Cited by 255
Incidence of Second Neoplasms in Patients with Bilateral Retinoblastoma
Roarty, J. D., McLean, I. W., & Zimmerman, L. E. (1988) · Ophthalmology · doi:10.1016/s0161-6420(88)32971-4 · Cited by 253
Trends in survival for childhood cancer in Britain diagnosed 1971–85
Stiller, C., & Bunch, K. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.383 · Cited by 140
Tumor Syndromes Predisposing to Osteosarcoma
Hameed, M., & Mandelker, D. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000190 · Cited by 109
Aran, V., Devalle, S., Meohas, W., Heringer, M., Cunha Caruso, A., Pinheiro Aguiar, D., Leite Duarte, M. E., & Moura Neto, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103340 · Cited by 87
Metadata
- Authors
- Draper, G. J., Sanders, B. M., & Kingston, J. E.
- Venue
- British Journal of Cancer
- Published
- 1986-05
- Volume
- 53
- Issue
- 5
- Pages
- 661-671
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2060658196
- Cited by
- 554
- References
- 16
- FWCI
- 15.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.